{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:43:23Z","timestamp":1783381403772,"version":"3.54.6"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"am","delay-in-days":651,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.berh.2023.101861","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:57:03Z","timestamp":1693342623000},"page":"101861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view"],"prefix":"10.1016","volume":"37","author":[{"given":"Ma\u00ebl","family":"Heiblig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Jamilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2023.101861_bib1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101861_bib2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms22041526","article-title":"The roles of the ubiquitin\u2013proteasome system in the endoplasmic reticulum stress pathway","volume":"22","author":"Qu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2023.101861_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrm2673","article-title":"Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways","volume":"10","author":"Schulman","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.berh.2023.101861_bib4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1242\/jcs.183954","article-title":"Ubiquitin chain diversity at a glance","volume":"129","author":"Akutsu","year":"2016","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.berh.2023.101861_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molcel.2009.01.014","article-title":"Nonproteolytic functions of ubiquitin in cell signaling","volume":"33","author":"Chen","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.berh.2023.101861_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/auto.5190","article-title":"Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome","volume":"4","author":"Ding","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.berh.2023.101861_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/cells11050851","article-title":"Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.berh.2023.101861_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cytogfr.2012.08.003","article-title":"Regulation of the innate immune system by ubiquitin and ubiquitin-like modifiers","volume":"23","author":"Oudshoorn","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.berh.2023.101861_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/biomedicines6020043","article-title":"The many roles of ubiquitin in NF-\u03baB signaling","volume":"6","author":"Courtois","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.berh.2023.101861_bib10","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/biomedicines10061250","article-title":"NF-\u03baB: a double-edged sword controlling inflammation","volume":"10","author":"Liu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.berh.2023.101861_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","article-title":"Ubiquitination in the regulation of inflammatory cell death and cancer","volume":"28","author":"Cockram","year":"2021","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.berh.2023.101861_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00365","article-title":"The balance of TNF mediated pathways regulates inflammatory cell death signaling in healthy and diseased tissues","volume":"8","author":"Webster","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.berh.2023.101861_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212459","article-title":"RIPK1 and TRADD regulate TNF-induced signaling and ripoptosome formation","volume":"22","author":"Feoktistova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2023.101861_bib14","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1038\/s41467-019-12033-8","article-title":"K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation","volume":"10","author":"Tang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2023.101861_bib15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/cdd.2017.67","article-title":"The small molecule that packs a punch: ubiquitin-mediated regulation of RIPK1\/FADD\/caspase-8 complexes","volume":"24","author":"Feltham","year":"2017","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.berh.2023.101861_bib16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.berh.2023.101861_bib17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.febslet.2009.12.047","article-title":"Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems","volume":"584","author":"Korolchuk","year":"2010","journal-title":"FEBS Letters"},{"key":"10.1016\/j.berh.2023.101861_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.molcel.2012.11.009","article-title":"Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity","volume":"49","author":"Py","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.berh.2023.101861_bib19","doi-asserted-by":"crossref","first-page":"8780","DOI":"10.3390\/ijms22168780","article-title":"NLRP3 ubiquitination-A new approach to target NLRP3 inflammasome activation","volume":"22","author":"Akther","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2023.101861_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41584-022-00778-4","article-title":"Disorders of ubiquitylation: unchained inflammation","volume":"18","author":"Beck","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2023.101861_bib21","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1093\/rheumatology\/keab392","article-title":"VEXAS syndrome in a woman","volume":"60","author":"Barba","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2023.101861_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3324\/haematol.2021.280238","article-title":"VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)","volume":"107","author":"Stubbins","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.berh.2023.101861_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2023.101861_bib24","series-title":"VEXAS syndrome is characterized by blood and tissues inflammasome pathway activation and monocyte dysregulation","author":"Kosmider","year":"2022"},{"issue":"13","key":"10.1016\/j.berh.2023.101861_bib25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib26","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1097\/HS9.0000000000000775","article-title":"UBA1 screening in sweet syndrome with hematological neoplasms reveals a novel association between VEXAS and chronic myelomonocytic leukemia","volume":"6","author":"Gurnari","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.berh.2023.101861_bib27","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib28","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2023.101861_bib30","series-title":"Clonal hematopoiesis in vexas syndrome","author":"Patel","year":"2022"},{"key":"10.1016\/j.berh.2023.101861_bib31","series-title":"Incidence, clinical associations, and Co-mutation Patterns of UBA1 Mutations in MDS","author":"Sirenko","year":"2022"},{"issue":"3","key":"10.1016\/j.berh.2023.101861_bib32","first-page":"244","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib33","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1097\/HS9.0000000000000868","article-title":"Recurrent mutations of the active adenylation domain of UBA1 in atypical form of VEXAS syndrome","volume":"7","author":"Faurel","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.berh.2023.101861_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nmd.2013.02.001","article-title":"Clinical and neuropathological features of X-linked spinal muscular atrophy (SMAX2) associated with a novel mutation in the UBA1 gene","volume":"23","author":"Dlamini","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.berh.2023.101861_bib35","first-page":"1","article-title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies","author":"Sakuma","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.berh.2023.101861_bib36","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/art.41743","article-title":"Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS","volume":"73","author":"Ferrada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101861_bib37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.chest.2022.10.011","article-title":"Pleuropulmonary manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome","volume":"163","author":"Borie","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.berh.2023.101861_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS","volume":"149","author":"van der Made","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.berh.2023.101861_bib39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.seminhematol.2021.10.007","article-title":"Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome","volume":"58","author":"Patel","year":"2021","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.berh.2023.101861_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/ejh.13944","article-title":"VEXAS syndrome: a review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation","volume":"110","author":"Cherniawsky","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.berh.2023.101861_bib42","first-page":"487","article-title":"Alcohol-induced vacuolization in bone marrow cells: ultrastructure and mechanism of formation","volume":"13","author":"Yeung","year":"1988","journal-title":"Blood Cell"},{"key":"10.1016\/j.berh.2023.101861_bib43","first-page":"203","article-title":"Vacuolization in myeloid and erythroid precursors in a child with menkes disease","volume":"36","author":"Say\u0131n","year":"2019","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.berh.2023.101861_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0148607194018002185","article-title":"Anemia and neutropenia due to copper deficiency in enteral nutrition","volume":"18","author":"Tamura","year":"1994","journal-title":"JPEN - J Parenter Enter Nutr"},{"key":"10.1016\/j.berh.2023.101861_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2018.1426454","article-title":"Pearson syndrome","volume":"11","author":"Farruggia","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.berh.2023.101861_bib46","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2022-169959","volume":"140","author":"Plesa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib47","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.berh.2023.101861_bib48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood-2016-09-741835","article-title":"Widespread and dynamic translational control of red blood cell development","volume":"129","author":"Alvarez-Dominguez","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib49","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1073\/pnas.92.11.4982","article-title":"Induction of ubiquitin-conjugating enzymes during terminal erythroid differentiation","volume":"92","author":"Wefes","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.berh.2023.101861_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan0218","article-title":"UBE2O remodels the proteome during terminal erythroid differentiation","volume":"357","author":"Nguyen","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.berh.2023.101861_bib51","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.berh.2023.101861_bib52","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1182\/blood-2022-165706","article-title":"Monocytopenia as an adverse prognosticator in vexas syndrome","volume":"140","author":"Kusne","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.exphem.2011.01.008","article-title":"Quiescence regulators for hematopoietic stem cell","volume":"39","author":"Li","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.berh.2023.101861_bib54","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/nature06256","article-title":"Regulation of cell cycle progression and gene expression by H2A deubiquitination","volume":"449","author":"Joo","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.berh.2023.101861_bib55","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.berh.2023.101861_bib56","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4161\/cc.19978","article-title":"Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage","volume":"11","author":"Moudry","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.berh.2023.101861_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bcmd.2010.05.009","article-title":"Hematopoietic cells from Ube1L-deficient mice exhibit an impaired proliferation defect under the stress of bone marrow transplantation","volume":"45","author":"Cong","year":"2010","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.berh.2023.101861_bib58","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib59","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.berh.2023.101861_bib60","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1038\/s41375-021-01353-8","article-title":"Prevalence of UBA1 mutations in MDS\/CMML patients with systemic inflammatory and auto-immune disease","volume":"35","author":"Zhao","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.berh.2023.101861_bib61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/10428194.2021.1973674","article-title":"Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases","volume":"63","author":"Dupuy","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.berh.2023.101861_bib62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.berh.2023.101861_bib63","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.3324\/haematol.2021.279418","article-title":"Dominance of an UBA1 mutant clone over a CALR mutant clone: from essential thrombocytemia to VEXAS","volume":"106","author":"Hage-Sleiman","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.berh.2023.101861_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0000000000000688","article-title":"Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease","volume":"29","author":"Cobo","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.berh.2023.101861_bib65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.11.008","article-title":"Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients","volume":"80","author":"Zhang","year":"2019","journal-title":"Exp Hematol"},{"key":"10.1016\/j.berh.2023.101861_bib66","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood.2022015384","article-title":"TET2-mutant clonal hematopoiesis and risk of gout","volume":"140","author":"Agrawal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib67","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101861_bib68","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101861_bib69","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.berh.2023.101861_bib70","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.berh.2023.101861_bib71","article-title":"New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: evolution from myelodysplastic syndrome to acute myeloid leukemia","volume":"71","author":"Battipaglia","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.berh.2023.101861_bib72","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2023.101861_bib73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.blre.2019.04.004","article-title":"Flaming and fanning: the Spectrum of inflammatory influences in myelodysplastic syndromes","volume":"36","author":"Banerjee","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.berh.2023.101861_bib74","doi-asserted-by":"crossref","first-page":"16188","DOI":"10.1073\/pnas.0607769103","article-title":"Impaired nucleotide excision repair upon macrophage differentiation is corrected by E1 ubiquitin-activating enzyme","volume":"103","author":"Nouspikel","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.berh.2023.101861_bib75","first-page":"2011","article-title":"Translating JAKs to jakinibs","volume":"204","author":"Gadina","year":"2020","journal-title":"JI"},{"key":"10.1016\/j.berh.2023.101861_bib76","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2023.101861_bib77","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.berh.2023.101861_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678927","article-title":"Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome","volume":"12","author":"Staels","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2023.101861_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jdcr.2022.02.022","article-title":"Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome","volume":"23","author":"Goyal","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2023.101861_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901063","article-title":"Case report: tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-year longitudinal observational study in Japan","volume":"13","author":"Kunishita","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2023.101861_bib81","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/annrheumdis-2021-220876","article-title":"Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan","volume":"80","author":"Kirino","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101861_bib82","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1097\/HS9.0000000000000661","article-title":"Azacytidine treatment for VEXAS syndrome","volume":"5","author":"Raaijmakers","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.berh.2023.101861_bib83","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.berh.2023.101861_bib84","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12185-023-03532-y","article-title":"Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome","volume":"117","author":"Kataoka","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.berh.2023.101861_bib85","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41409-021-01544-y","article-title":"Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report","volume":"57","author":"Loschi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.berh.2023.101861_bib86","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"Diarra","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.berh.2023.101861_bib87","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1002\/ajh.26786","article-title":"Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: data from a prospective series of patients","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.berh.2023.101861_bib88","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ajh.25950","article-title":"Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management","volume":"95","author":"Garcia-Manero","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.berh.2023.101861_bib89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101861_bib90","doi-asserted-by":"crossref","first-page":"A384","DOI":"10.1016\/j.revmed.2021.10.079","article-title":"Le VEXAS, un d\u00e9ficit immunitaire auto-inflammatoire","volume":"42","author":"Riescher","year":"2021","journal-title":"Rev Med Interne"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:40Z","timestamp":1761499420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521694223000475"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101861","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101861"}}